Diabetes and fractures: An overshadowed association

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 6, 2009, Pages 435-445

  Khazai, Natasha B ^a   Beck Jr , George R ^a,b   Umpierrez, Guillermo E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Advanced glycation end products; Bone mineral density; Fractures; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; CORTICOSTEROID; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; OPIATE; ORAL ANTIDIABETIC AGENT; PENTOSIDINE; PIOGLITAZONE; ROSIGLITAZONE; SEDATIVE AGENT;

ALCOHOLISM; AUTONOMIC NEUROPATHY; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FALL RISK; FALLING; FOOT FRACTURE; FRACTURE; GLYCATION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OSTEOBLAST; PATHOGENESIS; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; POSTMENOPAUSE; REVIEW; RISK; STROKE; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; WRIST FRACTURE;

ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RISK FACTORS;

EID: 70350786461     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328331c7eb     Document Type: Review

References (65)

1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and prediabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32:287-294.
2. Janghorbani M, Van Dam RM, WillettWC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495-505. (Pubitemid 47283633)
3. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: The Nurses' Health study. Diabetes Care 2006; 29:1573-1578. (Pubitemid 44127583)
4. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24:1192-1197.
5. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: A prospective study. J Clin Endocrinol Metab 2001; 86:32-38.
6. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: The health, aging, and body composition study. Arch Intern Med 2005; 165:1612-1617.
7. Forsen L,Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: Results from the Nord-Trondelag Health Survey. Diabetologia 1999; 42:920-925.
8. Ahmed LA, Joakimsen RM, Berntsen GK, et al. Diabetes mellitus and the risk of nonvertebral fractures: The Tromso study. Osteoporos Int 2006; 17:495-500.
9. de Liefde II, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam study. Osteoporos Int 2005; 16:1713-1720.
10. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type diabetes: The Women's Health Initiative Observational study. J Clin Endocrinol Metab 2006; 91:3404-3410.
11. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48:1292-1299.
12. van Daele PL, Stolk RP, Burger H, et al. Bone density in noninsulin-dependent diabetes mellitus. The Rotterdam study. Ann Intern Med 1995; 122:409-414.
13. Sosa M, Saavedra P, Jodar E, et al. Bone mineral density and risk of fractures in aging, obese postmenopausal women with type 2 diabetes. The GIUMO study. Aging Clin Exp Res 2009; 21:27-32.
14. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: Effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91:3355-3363.
15. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005; 16:1506-1512.
16. Heath H 3rd, Melton LJ 3rd, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980; 303:567-570.
17. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: A population-based study. Diabetes Care 2007; 30:835-841.
18. Weinstock RS, Goland RS, Shane E, et al. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res 1989; 4:97-101.
19. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007; 18:427-444. (Pubitemid 46354916)
20. Ottenbacher KJ, Ostir GV, Peek MK, et al. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol A Biol Sci Med Sci 2002; 57:M648-M653.
21. Holmberg AH, Johnell O, Nilsson PM, et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int 2006; 17:1065-1077.
22. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue Mountains Eye study. Diabetes Care 2001; 24:1198-1203.
23. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993; 137:1203-1211.
24. Kelsey JL, Browner WS, Seeley DG, et al. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. Am J Epidemiol 1992; 135:477-489.
25. Miao J, Brismar K, Nyren O, et al. Elevated hip fracture risk in type 1 diabetic patients: A population-based cohort study in Sweden. Diabetes Care 2005; 28:2850-2855.
26. Dennison EM, Syddall HE, Aihie Sayer A, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort study: Evidence for an indirect effect of insulin resistance? Diabetologia 2004; 47:1963-1968.
27. Vestergaard P. Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes 2009; 16:125-131.
28. Paul RG, Bailey AJ.Glycation of collagen: The basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996; 28:1297-1310.
29. Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001; 28:195-201.
30. Hein G, Weiss C, Lehmann G, et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65:101-104.
31. KumeS, KatoS,YamagishiS, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20:1647-1658.
32. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997; 8:260-270.
33. Wang X, Li X, Shen X, Agrawal CM. Age-related changes of noncalcified collagen in human cortical bone. Ann Biomed Eng 2003; 31:1365-1371.
34. Follak N, Kloting I, Wolf E, Merk H. Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone defect in spontaneously diabetic rats. Calcif Tissue Int 2004; 74:551-560. (Pubitemid 38780291)
35. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009; 94:2380-2386.
36. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int 2008; 83:324-331.
37. Nyomba BL, Verhaeghe J, Thomasset M, et al. Bone mineral homeostasis in spontaneously diabetic BB rats. I. Abnormal vitamin D metabolism and impaired active intestinal calcium absorption. Endocrinology 1989; 124: 565-572.
38. Christiansen C, Christensen MS, McNair P, et al. Vitamin D metabolites in diabetic patients: Decreased serum concentration of 24,25-dihydroxyvitamin D. Scand J Clin Lab Invest 1982; 42:487-491. (Pubitemid 12030397)
39. Bener A, Alsaied A, Al-Ali M, et al. High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 2008; 46:183-189.
40. Littorin B, Blom P, Scholin A, et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: Results from the Nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006; 49:2847-2852.
41. Di Cesar DJ, Ploutz-Snyder R, Weinstock RS, Moses AM. Vitamin D defi- ciency is more common in type 2 than in type 1 diabetes. Diabetes Care 2006; 29:174.
42. McNair P, Madsbad S, Christensen MS, et al. Bone mineral loss in insulintreated diabetes mellitus: Studies on pathogenesis. Acta Endocrinol (Copenh) 1979; 90:463-472.
43. McNair P, Christiansen C, Christensen MS, et al. Development of bone mineral loss in insulin-treated diabetes: A 1 1/2 years follow-up study in sixty patients. Eur J Clin Invest 1981; 11:55-59.
44. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005; 60:1157-1162.
45. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31:391-396.
46. Richardson JK, Hurvitz EA. Peripheral neuropathy: A true risk factor for falls. J Gerontol A Biol Sci Med Sci 1995; 50:M211-M215.
47. Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 1994; 271:128-133.
48. Greenspan SL, Myers ER, Kiel DP, et al. Fall direction, bone mineral density, and function: Risk factors for hip fracture in frail nursing home elderly. Am J Med 1998; 104:539-545.
49. Cundy TF, Edmonds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985; 2:461-464.
50. Kathol MH, el-Khoury GY, Moore TE, Marsh JL. Calcaneal insufficiency avulsion fractures in patients with diabetes mellitus. Radiology 1991; 180: 725-729.
51. Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 2001; 32:702-706.
52. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006; 29:1300-1306.
53. Lorini R, Scaramuzza A, Vitali L, et al. Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab 1996; 9 (Suppl 1):101-111. (Pubitemid 26122503)
54. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574-1576.
55. Solomon DH, Cadarette SM, Choudhry NK, et al. A Cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009; 94:2792-2798.
56. Mancini T, Mazziotti G, Doga M, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 2009 [Epub ahead of print].
57. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305-1310.
58. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349-3354.
59. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
60. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An Analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31:845-851.
61. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19:129-137.
62. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820-825.
63. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146:1226-1235.
64. Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004; 183:203-216.
65. Khazai N, Judd S, Tangpricha V. Calcium and vitamin D: Skeletal and extraskeletal health. Curr Rheumatol Rep 2008; 10:110-117.